JPMorgan Chase & Co. Cuts Roivant Sciences (NASDAQ:ROIV) Price Target to $15.00

Roivant Sciences (NASDAQ:ROIV – Free Report) had its price objective reduced by JPMorgan Chase & Co. from $16.00 to $15.00 in a report issued on Tuesday morning, Benzinga reports. They currently have an overweight rating on the stock. Several other research analysts also recently weighed in on ROIV. Truist Financial reissued a buy rating and […]

Related Keywords

United States ,American ,Eric Venker ,Analyst Recommendations For Roivant Sciences ,Goldman Sachs Group ,Roivant Sciences Trading Down ,Svf Investments Uk Ltd ,Citigroup Inc ,News Ratings For Roivant Sciences Daily ,Jpmorgan Chase Co ,Institutional Trading Of Roivant Sciences ,Cantor Fitzgerald ,Securities Exchange Commission ,York Mellon Corp ,Nasdaq ,Blackrock Inc ,Vanguard Group Inc ,Roivant Sciences ,Roivant Sciences Ltd ,American International Group Inc ,Free Report ,Moderate Buy ,Sciences Trading Down ,Svf Investments ,Exchange Commission ,New York Mellon Corp ,American International Group ,Get Free Report ,Sciences Ltd ,Roivant Sciences Daily ,Nasdaq Roiv ,Roiv ,Medical ,Lower Price Target ,